WOAG
WITHDRAWAL OF ATTORNEY GRANTED
03/06/2026
Voltar para busca
Dado oficial do USPTO
DUALASE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
38
Atualização mais recente
05/06/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
42
Data de depósito
05/08/2020
Data de registro
02/05/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
02/05/2023
Última transação
05/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Foreign priority
Primeiro uso
20/03/2018
Primeiro uso no comércio
20/03/2018
Código do desenho
4
Tipo de titular
03
Localização do titular
Toronto, Ontario, CA
Examinador
CANTOR, JILLIAN REDDING
Unidade examinadora
P10
Localização atual
TMO LAW OFFICE 137
Titulares e representantes
Titulares
Specific Biologics Inc.
Representantes
Specific Biologics Inc.
Classificação técnica
Classes Nice
Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 42
Pharmaceutical products development; Pharmaceutical research and developmentresearch in the field of gene editing; Pharmaceutical research services; Biomedical research services; Biotechnology researchin the field of genetic editing; Clinical research in the field of gene editing; Drug discovery services; Medical and scientific research in the field of cancer treatment; Medical and scientific research in the field of treatment of rare genetic diseases and disorders; Medical research; Medical research servicesfor the treatment of cystic fibrosis and lung cancer; Providing laboratory research services in the field of gene expressioncancer biology; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Research in the field of genetic editing; Research on the subject of pharmaceuticalspharmaceuticals to treat genetic disorderscystic fibrosis and lung cancer; Scientific investigations for medical purposes; Scientific research in the field of oncology; Scientific study and research in the field of oncology; Technical consulting in the field of pharmaceutical studies; Technical research in the field of pharmaceutical studies; Medical and scientific research in the field of genetic engineeringplatform gene editing technology; Consulting services in the fields of biotechnologypharmaceutical research and development and genetic science; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Scientific research in the field of genetics and genetic engineering; Platform as a service (PAAS) featuring computer software platforms for gene editing
Publicações
Histórico de despachos e eventos da marca no USPTO.
38 publicações encontradas
WOAR
TEAS WITHDRAWAL OF ATTORNEY RECEIVED
03/06/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
02/05/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
02/05/2023
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
25/03/2023
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
24/03/2023
DOCK
ASSIGNED TO EXAMINER
10/03/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
17/01/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
17/01/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
17/01/2023
ALIE
ASSIGNED TO LIE
17/01/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/01/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
17/07/2022
GNRT
NON-FINAL ACTION E-MAILED
17/07/2022
CNRT
SU - NON-FINAL ACTION - WRITTEN
17/07/2022
SUPC
STATEMENT OF USE PROCESSING COMPLETE
16/05/2022
IUAF
USE AMENDMENT FILED
10/05/2022
EISU
TEAS STATEMENT OF USE RECEIVED
10/05/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
16/12/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
16/12/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
16/12/2021
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
07/12/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/10/2021
PUBO
PUBLISHED FOR OPPOSITION
12/10/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
22/09/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/09/2021
DPCC
DIVISIONAL PROCESSING COMPLETE
11/08/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
02/08/2021
ALIE
ASSIGNED TO LIE
07/07/2021
DRRR
DIVISIONAL REQUEST RECEIVED
19/05/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
19/05/2021
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
19/05/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
29/11/2020
GNRT
NON-FINAL ACTION E-MAILED
29/11/2020
CNRT
NON-FINAL ACTION WRITTEN
29/11/2020
DOCK
ASSIGNED TO EXAMINER
28/11/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/09/2020
NWAP
NEW APPLICATION ENTERED
08/08/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace DUALASE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.